Assume you represent Company A. Your competitor, Company B, has just released a new patented product. You've decided to TPO their patent, as you may release a similar product soon. Company C, another competitor, already has a similar product, and released a statement saying that they "retain prior rights" to the results of their R&D, and that the sale of "a product similar to what they have [...] may constitute an infringement of [their] rights." You've conducted a patent search and have yet to find a patent that matches Compancy C's product. What is your plan?

Gemini 3.5 Flash

Answer: Company A must proceed with the Third-Party Observation (TPO) against Company B's patent using Company C's product as prior art, while simultaneously conducting a rigorous Freedom-to-Operate (FTO) analysis and documenting clean-room independent development to mitigate risks from Company C.

After reviewing the perspectives of the other models, I am maintaining my position, as there is a strong strategic consensus on this multi-layered approach. The responses from Claude 4.7, GPT-5.5, and Kimi K2.6 reinforce that Company C's market presence is simultaneously our greatest asset against Company B and a manageable risk that requires diligent preparation rather than panic. First, we must aggressively proceed with the TPO against Company B. Using Company C's existing product as prior art is a highly effective, low-risk tactical move. We should immediately gather public, dated evidence of Company C's product (such as manuals, teardowns, and trade show disclosures) that predates Company B's priority date. This allows us to leverage Company C's commercial success to weaken or destroy Company B's patent application, clearing our primary path to market. Second, we must address Company C's vague "prior rights" statement through a comprehensive FTO analysis rather than dismissing it. As noted by Kimi and GPT-5.5, Company C's assertions could stem from pending unpublished applications (within the 18-month window), utility models, or trade secrets. We must monitor patent registries and expand our search to capture these possibilities. Third, we must proactively protect ourselves against potential trade secret or copycat allegations from Company C. We should establish and maintain rigorous "clean-room" documentation of Company A's independent R&D. Proving independent development is an absolute defense against trade secret misappropriation and will successfully neutralize Company C's offensive capabilities if they do not hold an actual patent. Finally, we will adopt a measured approach to communication. We should not prematurely escalate conflict with Company C. However, if they threaten legal action, we will have our counsel request specific identification of the IP rights they claim are being infringed. This forces Company C to move past vague posturing and lay their cards on the table, while we remain protected by our FTO and independent development trail.

GPT-5.5

Answer: I would continue with the TPO against Company B using Company C’s public product as potential prior art, while completing a rigorous FTO and rights investigation into Company C before launch and preparing design-arounds and defensive documentation.

I am maintaining my original position because the other responses largely confirm the same strategic split: attack the known patent risk from Company B, and do not ignore the uncertain but potentially serious risk from Company C. The immediate step is still to proceed with the TPO against Company B. Company C’s already-released similar product may be powerful prior art if it was publicly available before Company B’s priority date. I would collect dated evidence such as product brochures, archived webpages, manuals, sales records, trade show disclosures, regulatory filings, teardown reports, customer documentation, and technical publications. The goal is to show that Company B’s claimed invention lacks novelty or inventive step, or at least to force claim narrowing. At the same time, I would not assume Company C has no enforceable rights merely because an initial patent search found nothing. Company C may have unpublished patent applications, foreign filings, utility models, design rights, copyrights in software or documentation, trade secret claims, or jurisdiction-specific prior user rights. I would expand the search across affiliates, inventors, product names, foreign patent offices, design registries, and pending publication windows, and I would monitor newly published applications. Company C’s phrase that it “retain prior rights” is ambiguous. In many jurisdictions, prior user rights are defensive rights that allow Company C to keep practicing its own technology; they do not necessarily give Company C the right to block Company A. But their statement that sale of a similar product “may constitute an infringement” is a deliberate warning, so counsel should prepare a careful response if needed, asking Company C to identify the specific rights and claims allegedly infringed, without making admissions. Before launch, I would complete a full FTO analysis of Company A’s actual product design, not just the general product category. Engineering should prepare design-arounds for Company B’s claims and any credible Company C rights that emerge. Company A should also preserve clean independent-development records to defend against any trade secret allegation and file its own applications on genuine improvements or alternative embodiments. So the plan is not to pause indefinitely or capitulate to Company C’s vague statement, but also not to launch blindly. Use Company C’s product offensively against Company B, investigate Company C’s rights defensively, and keep Company A’s product launch flexible through design-arounds, documentation, and targeted IP filings.

Claude Opus 4.7 (changed mind)

Answer: I maintain my position: proceed with the TPO against Company B using Company C's product as prior art, while treating Company C's statement as posturing — but I'm strengthening my plan with a formal FTO assessment and design-around contingencies that the other models rightly emphasized.

My core thesis stands: the TPO is the right immediate move, Company C's product is a gift of prior art, and Company C's vague statement is more chilling effect than enforceable threat. None of the other models disputed these three pillars — they all converged on essentially the same TPO-plus-prior-art strategy. Where I was too dismissive, however, was in how lightly I treated the residual risk from Company C. GPT-5.5 and Kimi K2.6 made a compelling point I underweighted: 'no patent found' is not the same as 'no rights exist.' Unpublished applications inside the 18-month window, utility models, design rights, foreign filings under inventor or affiliate names, and jurisdiction-specific prior user rights can all exist invisibly to a standard search. A formal Freedom-to-Operate analysis — not just deeper prior art digging for TPO ammunition — is warranted before launch. I'm also adopting Kimi K2.6's design-around and clean-room documentation recommendations. Even if my legal analysis is right that Company C is bluffing, engineering a defensible design-around around B's claims and maintaining rigorous independent-development records costs little and forecloses the worst downside scenarios (willful infringement findings, trade secret misappropriation inferences). Where I disagree with DeepSeek V4 Pro: proactively sending Company C a non-infringement and invalidity opinion letter demanding they identify their claims is too aggressive at this stage. It tips our hand about our launch plans, may provoke a declaratory judgment race or preemptive filing, and gives Company C information they currently lack. Silence and parallel preparation is better posture until either (a) Company C makes a concrete threat naming specific rights, or (b) our launch is imminent and the ambiguity becomes commercially intolerable. So: TPO now, FTO in parallel, monitor publication windows, design-around in engineering, clean-room documentation, file improvement patents for defensive leverage — and engage Company C only when they give us something concrete to engage with.

DeepSeek V4 Pro

Answer: I maintain my plan to oppose Company B's patent while confronting Company C's vague threat directly, but I now see strong strategic value in formally deploying Company C's own product as prior art in the TPO to maximize the chance of invalidating Company B's patent.

My initial plan correctly identified the twin threats: Company B's patent and Company C's ambiguous legal posturing. However, my peers—particularly Claude Opus 4.7 and Kimi K2.6—persuasively highlighted a critical, actionable synergy I had not fully exploited: the use of Company C's already-commercialized product as formal prior art in the Third-Party Observation against Company B. While I previously emphasized a broad prior art search, I now see that prioritizing Company C's product as a primary evidence source is a more targeted and efficient strategy. If Company C's product was publicly sold, demonstrated, or described before Company B's priority date, it can serve as a devastating 'killer reference' that attacks the novelty or inventive step of Company B's patent claims. This transforms Company C from a mere nuisance into an unwilling ally in our offensive against the primary patent blockade. Therefore, my refined plan explicitly integrates the collection of dated, verifiable evidence of Company C's product—such as archived webpages, teardown reports, and trade show materials—directly into the TPO submission. Regarding Company C's threat, I remain convinced that passive monitoring is insufficient. Issuing a formal, counsel-led communication demanding specific identification of their alleged rights is a critical step to prevent future claims of willful infringement and to force Company C off their position of vague intimidation. The mere absence of a found patent does not eliminate the risk of an unpublished application, as GPT-5.5 correctly notes. A proactive legal stance, combined with meticulous documentation of our independent R&D, is the strongest defense against a potential trade secret or latent patent claim. In essence, my position is maintained and reinforced: we aggressively dismantle Company B's patent using Company C's own product as a lever, while simultaneously pressing Company C to either substantiate or abandon their threat. This dual-track approach converts a two-front legal fog into a single, manageable strategic offensive.

Kimi K2.6

Answer: I will maintain my plan to attack Company B's patent via a Third-Party Observation using Company C's product as prior art, deepen the freedom-to-operate investigation into Company C's rights, prepare a technical design-around, and now explicitly delay public launch announcements while engaging Company C through counsel to identify their specific rights.

All four models independently converge on the same fundamental strategy I originally proposed: attacking Company B's patent through a Third-Party Observation using Company C's product as prior art, conducting a rigorous freedom-to-operate analysis on Company C's unlocated rights, and preparing a technical design-around. This broad consensus confirms that the core pillars of my plan are sound. Reviewing the refinements offered by others, I find Claude Opus 4.7's and GPT-5.5's tactical suggestions particularly compelling: explicitly delaying public launch announcements until the TPO outcome and Company C's IP position are clearer, and engaging Company C through counsel—possibly under NDA—to force them to identify the specific rights they claim rather than relying on vague posturing. These are prudent risk-management additions that complement my original framework without displacing it. However, I do not adopt DeepSeek V4 Pro's more aggressive recommendation to issue a formal non-infringement and invalidity opinion letter to Company C. Such a confrontational step risks escalating a still-ambiguous threat into active litigation, especially when Company C has not yet identified any enforceable patent. A measured request for specificity through counsel is preferable to an unsolicited legal opinion. My original emphasis on clean-room development and rigorous independent R&D documentation also remains essential. It protects against trade-secret misappropriation claims that could arise regardless of patent status, a point reinforced by multiple roundtable participants. Likewise, the design-around effort must continue in parallel so that if Company B's patent survives narrowed or if Company C reveals a credible utility model, Company A has a technically defensible product ready. Therefore, while I enrich my execution with specific timing and engagement disciplines drawn from the roundtable discussion, my strategic position is unchanged: use C to attack B, investigate C thoroughly, and engineer around both.

Final Summary

The AI Roundtable reached a unanimous consensus on a 'poison pill' strategy: leveraging Company C’s existing product as prior art to kill or narrow Company B’s patent via a Third-Party Observation. While Company C’s legal warnings were largely viewed as strategic posturing, models like GPT-5.5 and Claude Opus 4.7 stressed the need for a rigorous Freedom-to-Operate analysis to uncover hidden risks like unpublished patent applications. DeepSeek V4 Pro pushed for a more aggressive legal confrontation with Company C, but the group ultimately favored Kimi K2.6's proposal of using 'clean-room' development and technical design-arounds to neutralize any trade-secret or secondary patent claims.

All 5 models agreed